Phaseline

Targets › ITK

ITK (Tyrosine-protein kinase ITK/TSK): drug programs, companies and trials

3 programs from 2 companies in 16 trials: 7 Phase 3, 7 Phase 2, 2 Phase 1; Immunology, Oncology, Metabolic and endocrine; next expected readout Dec 2026.

Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. (UniProt, Q08881)

Open in Phaseline: the race on ITK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRitlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026
Corvus PharmaceuticalsSoquelitinib
ITK inhibitor
ITKPhase 3Peripheral T-Cell Lymphoma, Not Otherwise Specified; Atopic Dermatitis; Hidradenitis Suppurativa (HS); Autoimmune Lymphoproliferative SyndromeJun 2027
Corvus PharmaceuticalsCPI-818
Interleukin-2 inducible T-cell kinase (ITK) inhibitor
ITKPhase 1T-cell LymphomaDec 2026

Conditions

Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Peripheral T-Cell Lymphoma, Not Otherwise Specified (1) Atopic Dermatitis (1) Hidradenitis Suppurativa (HS) (1) Autoimmune Lymphoproliferative Syndrome (1) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (3)

Companies

Corvus Pharmaceuticals (2) Pfizer (1)

Related targets

JAK3 (1) BMX (1) TEC (1) TXK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.